The proportions of women with CIN 2+ and CIN 3+ on excisional procedure within 24 months of CIN 1 cervical biopsy were calculated with binomial exact CIs.

Emily Fukuchi, MD; Barbara Fetterman, SCT (ASCP); Nancy Poitras, ACS, PMP; Walter Kinney, MD; Thomas Lorey, MD; Ramey D. Littell, MD To evaluate whether the presence of CIN 1 on ECC contributes to ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

One of those targets is cervical cancer ... of a type of precancerous condition called cervical intraepithelial neoplasia grade 3 (CIN3). While this is a group of abnormal precancerous cells ...

including Grade 1, 2, and 3 anal intraepithelial neoplasia, according to Merck. Regarding the approval of the vaccine, Tian Anna, Senior Vice President of Merck Global and President of Merck China ...

1 Department of Gynecology ... were reviewed by two senior pathologists from Yunnan First People’s Hospital. Diagnoses of cervical intraepithelial neoplasia (CIN I–III) and cervical cancer were made ...